11/15
10:33 am
edit
Editas Medicine (NASDAQ:EDIT) was upgraded by analysts at Chardan Capital from a "hold" rating to a "strong-buy" rating.
Low
Report
Editas Medicine (NASDAQ:EDIT) was upgraded by analysts at Chardan Capital from a "hold" rating to a "strong-buy" rating.
11/10
07:11 am
edit
Editas Medicine Announces Third Quarter 2025 Results and Business Updates [Yahoo! Finance]
Medium
Report
Editas Medicine Announces Third Quarter 2025 Results and Business Updates [Yahoo! Finance]
11/10
07:00 am
edit
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
Medium
Report
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
11/3
09:00 am
edit
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
Low
Report
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
10/24
12:21 pm
edit
Editas Medicine (NASDAQ:EDIT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Editas Medicine (NASDAQ:EDIT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/9
11:01 am
edit
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Low
Report
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
10/8
12:20 pm
edit
Editas Medicine (NASDAQ:EDIT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Editas Medicine (NASDAQ:EDIT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/6
09:00 am
edit
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
Medium
Report
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
9/29
01:06 am
edit
Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program [Yahoo! Finance]
Medium
Report
Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program [Yahoo! Finance]
9/25
09:15 am
edit
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
Low
Report
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
9/25
09:15 am
edit
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
Low
Report
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus